AstraZeneca PLC AZN
Annual report 2023
added 11-16-2024
Country |
Britain |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Mr. Pascal Soriot M.B.A. |
Employees in the company |
70 600 |
Shares |
- |
Market Cap[1] |
$ 96.9 B |
EBITDA (LTM) |
$ 3.67 B |
P/E (LTM) |
46.96 |
P/S (LTM) |
7.88 |
EPS (LTM) |
1.36 |
AstraZeneca is a global biopharmaceutical company specializing in the research, development, and commercialization of drugs for the treatment of diseases in various therapeutic areas. The company was founded in 1999 through the merger of Astra AB and Zeneca Group plc and is headquartered in Cambridge, UK.
AstraZeneca operates in over 100 countries and employs more than 70,000 people worldwide. The company is a leader in the research and development of drugs for the treatment of cancer, cardiovascular disease, respiratory diseases, diabetes, and other serious illnesses.
AstraZeneca's portfolio includes a wide range of drugs, including some of the world's best-selling drugs such as Crestor, Symbicort, and Nexium. The company invests heavily in research and development to develop innovative therapies that can improve patients' lives and health. Is also committed to promoting sustainable and responsible business practices. The company aims to be carbon neutral by 2025 and reduce its impact on the environment. It has also implemented programs to support communities and patients around the world.
In recent years, AstraZeneca has made several significant acquisitions, including MedImmune, Pearl Therapeutics, and Alexion Pharmaceuticals. These acquisitions have helped expand the company's portfolio and strengthen its position as a leading biopharmaceutical company.
In summary, AstraZeneca is a global biopharmaceutical company with a strong commitment to research and development, sustainability, and social responsibility. Its products and services have a significant impact on the healthcare industry and the lives of millions of people worldwide.
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.